| Similar Articles |
|---|
 |
The Motley Fool
September 27, 2010
Brian Orelli |
Better Buy: Ariad Pharmaceuticals or Corcept Therapeutics? A battle of drugless companies looking for their first hit.   |
The Motley Fool
December 23, 2010
Brian Orelli |
Corcept May Have Hit Pay Dirt Corcept's Corlux tackles Cushing's syndrome. |
Pharmaceutical Executive
October 1, 2006
Beth Herskovits |
Born Again Mifepristone is best known as an abortion drug. But it appears to be on the verge of a second career - treating a severe form of major depression. |
The Motley Fool
September 23, 2010
Brian Orelli |
Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease. |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
